10 АНГЛІЙСЬКА КНИЖКИ ПОВ'ЯЗАНІ ІЗ «RITONAVIR»
Дізнайтеся про вживання
ritonavir з наступної бібліографічної підбірки. Книжки пов'язані зі словом
ritonavir та короткі уривки з них для забезпечення контексту його використання в англійська літературі.
1
HIV and Psychiatry: Training and Resource Manual
With respect to the concomitant use of antiretrovirals, significant interactions with
paroxetine and fluoxetine are expected with regimens containing ritonavir. In fact,
a case series of serotonin syndromes has been reported with the concomitant ...
Kenneth Citron, Marie Josée Brouillette, Alexandra Beckett, 2005
2
Oral Lipid-Based Formulations: Enhancing the Bioavailability ...
Ritonavir, an HIV protease inhibitor with a peptide-like structure, has an intrinsic
water solubility of 1.0 g/mL and two weakly basic thia- zole groups with pKa's of
1.8 and 2.6, which preclude the possibility of solubilization through manipulation
...
3
Drug Therapy in Nursing
It is a pregnancy category B drug, and recommendations for its use during
pregnancy are the same as those for saquinavir. Ritonavir Ritonavir (RTV, Norvir)
is an oral PI used to treat HIV infection. It is available as a capsule or oral
suspension.
Diane S. Aschenbrenner, Samantha J. Venable, 2009
4
Foye's Principles of Medicinal Chemistry
O O NH O H N N H O S N S N O H N O N H N OH H N N OH N N H CH3 OH C O
NH 2 O NH H H H3CSO3H Saquinavir O O OH H N S O O N CF 3 H O N H N OH
C O NH H S CH 3 HO H3CSO3H Nelfinavir OH H CH3 O N O CH3 Ritonavir OO ...
Thomas L. Lemke, David A. Williams, 2012
5
Gibaldi's Drug Delivery Systems in Pharmaceutical Care
Ritonavir itself is both a potent inhibitor and a potent inducer of cytochrome P-450
enzymes. In fact, it is capable of inducing its own metabolism (autoinduction).33
Although circumoral paresthesias occur in up to 25% of patients taking ritonavir, ...
Mary Lee, Archana Desai, 2007
6
Applied Pharmacokinetics & Pharmacodynamics: Principles of ...
exist for ritonavir-boosted amprenavir and nelfinavir combinations at this time.16
Nelfinavir may be considered as an alternative to ritonavir in enhancing
saquinavir (SGC) concentrations in cases in which ritonavir is contraindi- cated.
16 ...
7
Litt's Drug Eruption Reference Manual Including Drug ...
... with ritonavir) Clinically important, potentially hazardous interactions with:
astemizole, carbamazepine, cisapride, dihydroergotamine, ergotamine,
lovastatin, midazolam, phenobarbital, phenytoin, pimozide, pravastatin, rifampin,
saquinavir, ...
8
Drug Interactions in Infectious Diseases
can be administered alone at a dose of 400 mg once daily or with ritonavir at a
dose of 300 mg atazanavir/100 mg ritonavir once daily. The majority of clinical
atazanavir use is in combination with ritonavir since it provides higher plasma
levels.
Stephen C. Piscitelli, Keith A. Rodvold, Manjunath P. Pai, 2011
9
Global HIV/AIDS Medicine
Kaletra® is a fixed-dose combination of the protease inhibitor lopinavir with a low
dose of ritonavir 400/100 mg twice daily, abbreviated LPV/r. [It is customary to
use a lower case 'r' when abbreviating The low doses of ritonavir used as a PK ...
10
WHO Model Formulary 2008
... anticoagulant effect) Ritonavir Zidovudine Manufacturer of zidovudine advises
avoid concomitant use * Amitriptyline Plasma concentration possibly increased
by ritonavir * Amlodipine Possibly increased plasma concentration of amlodipine
...
Mark C. Stuart, Maria Kouimtzi, Suzanne Hill, 2009
НОВИНИ ІЗ ТЕРМІНОМ «RITONAVIR»
Дізнайтеся, що обговорювала національна та міжнародна преса, і як термін
ritonavir вживається в контексті наступних новин.
Tentative FDA approval of lopinavir/ritonavir oral pellet formulation …
"The announcement of tentative FDA approval of the lopinavir/ritonavir oral pellet formulation is an important step forward in increasing access to World Health ... «News-Medical.net, Червень 15»
US FDA approves Cipla's Lopinavir, Ritonavir to treat AIDS in infants
The pharma giant has introduced an innovative formulation of Lopinavir and Ritonavir to treat AIDS in Infants. The formulation includes Lopinavir/ritonavir (LPV/r) ... «DoctorPulse.co, Червень 15»
Cipla Gets US Regulator's Nod for Lopinavir, Ritonavir Oral Pellets
New Delhi: Drug major Cipla has received approval from US health regulator USFDA for Lopinavir and Ritonavir oral pellets used for treating AIDS in infants and ... «NDTV, Червень 15»
AbbVie Presents New Data for its Investigational Hepatitis C …
AbbVie's investigational, two direct-acting antiviral treatment consists of ombitasvir/paritaprevir/ritonavir and is currently under priority review by the Japanese ... «PR Newswire, Травень 15»
Eiger Bio Announces Interim Results of Lonafarnib in Combination …
LOWR HDV - 1 (LOnafarnib With and without Ritonavir-1) is a parallel dose comparison study which randomized subjects to receive different doses of lonafarnib ... «PR Newswire, Квітень 15»
Eiger BioPharmaceuticals Announces Abstracts and Presentations …
Data from the Phase 2 study of lonafarnib boosted with ritonavir in patients infected with HDV will be presented for the first time. The accepted abstracts, related ... «PR Newswire, Квітень 15»
Ritonavir concentrations not correlated with lipid levels in people …
People taking HIV treatment based on ritonavir-boosted atazanavir and darunavir have comparable long-term increases in lipid levels, investigators from the ... «aidsmap, Квітень 15»
Antiretrovirals Linked to Cumulative Kidney Risk
SEATTLE — In patients with HIV who are taking tenofovir, ritonavir-boosted atazanavir, or ritonavir-enhanced lopinavir, the risk for chronic kidney disease ... «Medscape, Лютий 15»
Ombitasvir, Paritaprevir Co-dosed With Ritonavir, Dasabuvir, and …
Ombitasvir, Paritaprevir Co-dosed With Ritonavir, Dasabuvir, and Ribavirin for Hepatitis C in Patients Co-infected With HIV-1: A Randomized Trial. Mark S. «JAMA: The Journal of the American Medical Association, Лютий 15»
Results from AbbVie's Study of VIEKIRA PAK™ (ombitasvir …
The ritonavir component of VIEKIRA PAK is an HIV-1 protease inhibitor and can select for HIV-1 protease inhibitor resistance. To reduce this risk, HCV/HIV-1 ... «PR Newswire, Лютий 15»
